Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and leukemia group B 9264

Journal of Clinical Oncology

Volumn 16, Issue 5, 1998, Pages 1811-1819

  Venook, Alan P ^a   Egorin, Merrill J ^a   Rosner, Gary L ^a   Brown, Thomas D ^a   Jahan, Thierry M ^a   Batist, Gerald ^a   Hohl, Raymond ^a   Budman, Daniel ^a   Ratain, Mark J ^a   Kearns, Christine M ^a   Schilsky, Richard L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE LIVER FUNCTION RELATION; DOSE RESPONSE; DRUG ELIMINATION; DRUG METABOLISM; DRUG RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LIVER DYSFUNCTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT OUTCOME;

EID: 0031832839     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.5.1811     Document Type: Article

References (19)

1. McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989
2. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
3. Motzer RJ, Chou TC, Schwartz L, et al: Paclitaxel in germ cell cancer. Semin Oncol 22:12-15, 1995
4. Murphy WK, Fossella FV, Winn RJ, et al: Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85:384-388, 1993
5. Ajani JA, Ilson DH, Daugherty K, et al: Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86:1086-1091, 1994
6. Rowinsky EK, Donehower RC: Paclitaxel (Taxol). N Engl J Med 332:1004-1014, 1995
7. Gianni L, Kearns CM, Giani A, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13:180-190, 1995
8. Wilson WH, Berg SL, Bryant G, et al: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion. J Clin Oncol 12:1621-1629, 1994
9. Seidman AD, Hochhauser D, Gollub M, et al: Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 14:1877-1884, 1996
10. 2 dose in combination with granulocyte colony-stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 33:48-52, 1993
11. Glantz MJ, Choy H, Kearns CM, et al: Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. J Natl Cancer Inst 87:1077-1081, 1995
12. Jamis-Dow CA, Klecker RW, Katki AG, et al: Metabolism of Taxol by human and rat liver in vitro: A screen for drug interactions and interspecies differences. Cancer Chemother Pharmacol 36:107-114, 1995
13. D'Argenio DZ, Schumitzky A: A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9:115-134, 1979
14. Kearns CM, Gianni L, Egorin MJ: Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 22:16-23, 1995
15. Kearns CM, Sridhara R, Grasela DM, et al: Comparative differences in paclitaxel pharmacokinetics between Japanese and European/American patients. Proc Am Soc Clin Oncol 15:473, 1996 (abstr)
16. Brenner DE, Wiernik PH, Wesley M, et al: Acute doxorubicin toxicity: Relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia Cancer 53:1042-1048, 1984
17. Van den Berg HW, Desai ZR, Wilson R, et al: The pharmacokinetics of vincristine in man: Reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol 8:215-219, 1982
18. Huizing MT, Keung ACF, Rosing H, et al: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11:2127-2135, 1993
19. Tamura T, Sasaki Y, Nishiwaki Y, et al: Phase I and pharmacokinetic study of paclitaxel administered by 3-hour infusion. Proc Am Soc Clin Oncol 13:132, 1994 (abstr)